Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
Dexcom (NASDAQ: DXCM) has been selected by the U.S. Food and Drug Administration as the first participant in the FDA’s Technology-Enabled Meaningful Patient Outcomes (TEMPO) Digital Health Devices Pilot Program, an initiative to evaluate digital health technologies for chronic disease management using real-world evidence.
According to Dexcom, participation will enable an AI-powered glucose health program that integrates data from Dexcom G7 and Stelo with contextual information such as nutrition, activity, sleep and stress. The program is intended to support prediabetes and Type 2 diabetes screening, help improve glycemic control and HbA1c in people with prediabetes, and inform earlier intervention and broader cardiometabolic outcomes, while leveraging Dexcom’s clinician software platform for population-level care personalization.
Dexcom (NASDAQ: DXCM) announced that Health Canada has authorized the Dexcom G7 15 Day continuous glucose monitoring (CGM) system for adults 18+ with diabetes. According to Dexcom, G7 15 Day is the longest‑lasting and most accurate CGM system authorized by Health Canada, offering real-time glucose readings for up to 15.5 days per sensor and reporting an overall MARD of 8.0%.
The system is designed to lower sensor change frequency, simplify diabetes management and reduce waste, while retaining existing G7 features such as waterproof† sensors, direct-to-Apple Watch‡ connectivity, a 12‑hour sensor grace period, Dexcom Clarity app integration, data sharing with caregivers, and customizable alerts. While authorized, Dexcom G7 15 Day is not yet available for purchase in Canada; Dexcom plans education and support for patients and providers ahead of launch and invites Canadians to register online for availability updates.
Dexcom (NASDAQ:DXCM) will release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will host a conference call at 4:30 p.m. Eastern Time, with a concurrent webcast and archived replay on the Dexcom investor relations website.
Dexcom (NASDAQ: DXCM) announced key Stelo milestones at Aspen Ideas: Health. Stelo received expanded FDA clearance for pediatric use in children from age 2 not using insulin. A fully reimagined Stelo app will launch in July in the US, with international rollouts planned in the UK, Australia, New Zealand and South Korea through 2027.
Dexcom (NASDAQ:DXCM) reported results from the CONNECT randomized controlled trial in adults with Type 2 diabetes not using insulin. Using Dexcom G7 CGM led to a 1.6% average A1C reduction (0.9% greater than control), improved time-in-range, lower hyperglycemia, and higher treatment satisfaction over 26 weeks.
Dexcom (NASDAQ:DXCM) highlighted new clinical, product and strategic initiatives at ADA 2026 to broaden continuous glucose monitoring (CGM) use, especially for people with Type 2 diabetes not on insulin.
Key updates include CONNECT trial data, an FDA-cleared reimagined Stelo app, and the planned acquisition of Nutrisense to add personalized nutrition coaching.
Dexcom (NASDAQ:DXCM) released its first Customer Advisory Council Report, sharing feedback from people with diabetes, caregivers, clinicians and advocates, and outlining six specific commitments to enhance product performance and user experience.
Dexcom is making the Council permanent and will provide regular 2026 updates on progress against these commitments.
Summary not available.
Dexcom (Nasdaq: DXCM) announced Dexcom Flex, a new continuous glucose monitoring (CGM) system for adults with Type 2 diabetes who are not on intensive insulin therapy. The system will launch in Germany soon.
Dexcom Flex offers 24/7 glucose readings on smartphones, smartwatches or a receiver without routine fingerpricks, plus optional low alerts, food and activity logging, and personalised insights. It is aimed at people using basal insulin, oral medications or GLP‑1 receptor agonists and is intended to broaden CGM access and support earlier, more tailored Type 2 diabetes management. Dexcom cites research indicating CGM use in Type 2 diabetes may be associated with fewer hospitalisations, reduced long-term complications and improved confidence in managing glucose levels.
Dexcom (NASDAQ:DXCM) announced governance changes ahead of its 2026 Investor Day. The company plans to add two new independent directors with MedTech leadership or lean operations experience, identified in collaboration with Elliott Investment Management.
Dexcom will also rename its Board Technology Committee as the Operations and Innovation Committee, expanding its mandate to cover operations, quality and the technical roadmap. With the planned appointments, Dexcom will have added six new independent directors since early 2023.